HCV NS3 Oligonucleotide Primers for Nested PCR Amplification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current DNA sequencing assays for the HCV NS3 region have limited performance due to high variability of the HCV genome, particularly for genotypes 1a and 1b, leading to poor sensitivity in reverse transcription followed by PCR-based amplification, which is not widely accepted in clinical laboratories and lacks regulatory approval.
Innovation Solution
The development of specific oligonucleotide sequences (SEQ ID NOS: 1-45) for amplification primers that are designed to target the NS3 gene of HCV genotypes 1a and 1b, enabling high-performance nested PCR and sequencing, with primer sets like Primer Set 1-14, which achieve >95% successful amplification across global sequence variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional PCR-based amplification methods are used for HCV NS3 region, then the assay can be performed with standard protocols, but the sensitivity is poor due to high genome variability particularly for genotypes 1a and 1b
Solution Approach 1:
The patent applies local quality by designing primers with specific sequence characteristics tailored to target different HCV genotype regions. The primers contain specific nucleotide sequences (e.g., 5'-GGTGGAGGTTGCTGGC-3' for genotype 1a, 5'-GCTGGTGGRGAGGARTTGTC-3' for genotype 1b) that are optimized for binding to particular genomic regions, allowing selective and sensitive detection of different HCV variants while maintaining high amplification success rates
Solution Approach 2:
The patent employs parameter changes by modifying primer sequences to account for genome variability. Different primer sequences are designed with specific nucleotide compositions and lengths to match the variability in HCV genotypes 1a and 1b. The primers are engineered with specific Tm values and GC content parameters to ensure optimal binding under standardized PCR conditions, thereby improving both sensitivity and reliability across different genotypes
2Ease of manufacture
If standard primer sequences are used for HCV amplification, then the assay design is simple, but the performance is limited and not widely accepted in clinical laboratories
Solution Approach 1:
The patent achieves universality by developing a panel of primers that can detect multiple HCV genotypes (1a, 1b, and other variants) using a standardized nested PCR protocol. The primer sets are designed to be universally applicable across different laboratory settings while maintaining high performance. The same basic assay framework can detect various HCV variants by simply changing the primer sequences, making the method both simple to manufacture and clinically acceptable
Solution Approach 2:
The patent applies dynamics by creating a flexible primer system that can adapt to different HCV genotype requirements. The primer sequences are designed with variable regions that can be adjusted based on the target genotype, allowing the same basic assay protocol to dynamically target different viral variants. This dynamic adaptability ensures both ease of manufacture through standardized protocols and reliability through genotype-specific optimization
3Measurement precision
If nested PCR with specific oligonucleotide sequences is implemented, then detection sensitivity and amplification success rate improve to >95%, but the assay complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the HCV NS3 genome into specific target regions that can be amplified by distinct primer pairs. The nested PCR protocol segments the amplification process into an outer PCR step followed by an inner PCR step, each targeting specific regions with dedicated primers. This segmentation allows high detection sensitivity for each genotype while organizing the complexity into manageable, standardized steps that can be systematically implemented in clinical laboratories
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These oligonucleotide sequences result in uniquely high performing assay designs that meet commercialization criteria, demonstrating sufficient sensitivity for routine clinical use and allowing for the detection of mutations associated with resistance to protease inhibitors in the NS3 region of HCV.
Implementation Method 1
The primers are used in nested PCR methods for the detection or sequencing of HCV NS3
Implementation Method 2
nucleic acid amplifications of HCV
Data Source
AI summary
The present disclosure relates to oligonucleotide sequences for amplification primers and their use in performing nucleic acid amplifications of HCV, in particular regions that encode the NS3 polypeptide. In some embodiments the primers are used in nested PCR methods for the detection or sequencing of HCV NS3. The oligonucleotide sequences are also provided assembled as kits that can be used to amplify and detect or sequence HCV NS3.